

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Section 1: Identification

Product name : Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Reproductive toxicity : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Immune system)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H372 Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 10.1 Revision Date: 15.10.2025 SDS Number: 7723971-00018 Date of last issue: 14.04.2025
Date of first issue: 06.01.2021

P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Pembrolizumab	1374853-91-4	≥ 10 -< 20
Sucrose	57-50-1	≥ 1 -< 10
Berahyaluronidase alfa	2636716-20-4	< 0.1

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 10.1	Revision Date: 15.10.2025	SDS Number: 7723971-00018	Date of last issue: 14.04.2025 Date of first issue: 06.01.2021
-----------------	------------------------------	------------------------------	---

Notes to physician : when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version 10.1 Revision Date: 15.10.2025 SDS Number: 7723971-00018 Date of last issue: 14.04.2025
Date of first issue: 06.01.2021

employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Pembrolizumab	1374853-91-4	TWA	450 µg/m ³ (OEB 2)	Internal
Sucrose	57-50-1	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 10.1 Revision Date: 15.10.2025 SDS Number: 7723971-00018 Date of last issue: 14.04.2025
Date of first issue: 06.01.2021

Berahyaluronidase alfa	2636716-20-4	TLV-C	0.06 ug/m3 (OEB 5)	Internal
	Further information: RSEN			
		Wipe limit	0.07 ug/100 cm2	

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version 10.1	Revision Date: 15.10.2025	SDS Number: 7723971-00018	Date of last issue: 14.04.2025 Date of first issue: 06.01.2021
-----------------	------------------------------	------------------------------	---

Section 9: Physical and chemical properties

Appearance	: liquid
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: 5.5 No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity Viscosity, kinematic	: No data available
Explosive properties	: Not explosive

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

Acute toxicity

Not classified based on available information.

Components:**Sucrose:**

Acute oral toxicity	:	LD50 (Rat): 29,700 mg/kg
---------------------	---	--------------------------

Berahyaluronidase alfa:

Acute oral toxicity	:	Remarks: Not classified due to lack of data.
Acute inhalation toxicity	:	Remarks: Not classified due to lack of data.
Acute dermal toxicity	:	Remarks: Not classified due to lack of data.

Skin corrosion/irritation

Not classified based on available information.

Components:**Berahyaluronidase alfa:**

Remarks	:	Not classified due to lack of data.
---------	---	-------------------------------------

Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Berahyaluronidase alfa:**

Remarks : Not classified due to lack of data.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Berahyaluronidase alfa:**

Result : Sensitiser

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Sucrose:**Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative**Berahyaluronidase alfa:**

Genotoxicity in vitro : Remarks: Not classified due to lack of data.

Genotoxicity in vivo : Remarks: Not classified due to lack of data.

Germ cell mutagenicity - : May cause genetic defects.
Assessment**Carcinogenicity**

Not classified based on available information.

Components:**Berahyaluronidase alfa:**

Remarks : Not classified due to lack of data.

Reproductive toxicity

May damage the unborn child.

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Components:**Pembrolizumab:**

Reproductive toxicity - Assessment : May damage the unborn child., Based on data from similar materials

Berahyaluronidase alfa:

Effects on fertility : Remarks: Not classified due to lack of data.
May cause adverse reproductive effects.

Effects on foetal development : Remarks: Not classified due to lack of data.
May cause birth defects.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

STOT - single exposure

Not classified based on available information.

Components:**Berahyaluronidase alfa:**

Assessment : May cause damage to organs.
Remarks : Not classified due to lack of data.

STOT - repeated exposure

Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Components:**Pembrolizumab:**

Target Organs : Immune system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Berahyaluronidase alfa:

Assessment : May cause damage to organs through prolonged or repeated exposure.
Remarks : Not classified due to lack of data.

Repeated dose toxicity**Components:****Pembrolizumab:**

Species : Monkey
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Species : Dog
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.
May cause damage to organs.

Aspiration toxicity

Not classified based on available information.

Components:**Berahyaluronidase alfa:**

Not applicable

Experience with human exposure**Components:****Pembrolizumab:**

Inhalation : Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

Berahyaluronidase alfa:

General Information : Avoid repeated exposure.
May cause eye, skin, and respiratory tract irritation.
May be harmful if swallowed.
May be harmful if inhaled.
May produce an allergic reaction.
May cause heritable genetic damage.
May cause adverse reproductive effects.
May cause birth defects.
May cause damage to organs.

Further information**Components:****Berahyaluronidase alfa:**

Remarks : The toxicological properties of this material have not been fully investigated

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Section 12: Ecological information

Ecotoxicity**Components:****Berahyaluronidase alfa:**

Toxicity to fish : Remarks: No data available

Toxicity to daphnia and other aquatic invertebrates : Remarks: No data available

Toxicity to algae/aquatic plants : Remarks: No data available

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : Remarks: No data available

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Persistence and degradability**Components:****Berahyaluronidase alfa:**

Biodegradability : Remarks: No data available

Stability in water : Remarks: No data available

Bioaccumulative potential**Components:****Sucrose:**

Partition coefficient: n-octanol/water : Pow: < 1

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

Not regulated as a dangerous good

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Environmentally hazardous	: no

IATA-DGR

Not regulated as a dangerous good

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Packing instruction (cargo aircraft)	: Not applicable
Packing instruction (passenger aircraft)	: Not applicable

IMDG-Code

Not regulated as a dangerous good

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

Not regulated as a dangerous good

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard 2020

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

CA. DSL : not determined

AICS : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 15.10.2025

Further informationSources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for

Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
10.1	15.10.2025	7723971-00018	Date of first issue: 06.01.2021

Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN